QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Abramson Cancer Center at Penn Medicine

Summary

This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Women and men age \> 18 years * Metastatic breast cancer, histologically- confirmed. Any estrogen receptor (ER) status is allowed. ER status will be determined by local laboratory assessment utilizing ASCO/CAP guidelines. * Primary and/or metastatic tumor with 1+ level of expression of HER2 by immunohistochemistry as determined by local laboratory assessment utilizing ASCO/CAP guidelines. * Measurable disease by cross-sectional imaging at the start of treatment. Patients with measurable bone-only disease or active brain metastases are eligible. * Archival tissue availabl…

Locations (37)

University of California San Francisco Medical Center
San Francisco, California
Emma.Brophy@ucsf.edu
Smilow Cancer Hospital-Derby Care Center
Derby, Connecticut
carl.brown@yale.edu
Smilow Cancer Hospital Care Center
Fairfield, Connecticut
carl.brown@yale.edu
Smilow Cancer Hospital at Glastonbury
Glastonbury, Connecticut
carl.brown@yale.edu
Smilow Cancer Hospital Care Center at Greenwich
Greenwich, Connecticut
carl.brown@yale.edu
Smilow Cancer Hospital Care Center
Guilford, Connecticut
carl.brown@yale.edu

Summary

Eligibility

Interventions

Locations (37)